Individually dosed omalizumab: an effective treatment for severe peanut allergy
Clinical & Experimental Allergy2016Vol. 47(4), pp. 540–550
Citations Over TimeTop 10% of 2016 papers
Josef Brändström, Mirja Vetander, G. Lilja, S. G. O. Johansson, A.‐C. Sundqvist, Frida Kalm, Caroline Nilsson, Anna Nopp
Abstract
Individually dosed omalizumab, monitored by CD-sens, is an effective and safe treatment for severe peanut allergy. The ratio of IgE-ab to storage protein Ara h 2/IgE as well as CD-sens to peanut may predict the need of a higher omalizumab dose. Clinical trials numbers: EudraCT; 2012-005625-78, ClinicalTrials.gov; NCT02402231.
Related Papers
- → Omalizumab therapy is associated with reduced circulating basophil populations in asthmatic children(2014)42 cited
- → The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes(2021)34 cited
- → Improved FcεRI-Mediated CD203c Basophil Responsiveness Reflects Rapid Responses to Omalizumab in Chronic Spontaneous Urticaria(2020)11 cited
- → Kinetic Profiling of Clinical Symptoms and Basophil Parameters During Treatment of Chronic Spontaneous Urticaria with Omalizumab(2019)2 cited
- → Faculty Opinions recommendation of The Efficacy of Omalizumab Treatment in Chronic Spontaneous Urticaria is Associated with Basophil Phenotypes.(2021)